Knee cartilage repair: new cell therapy shows promise in small study

NCT ID NCT02539069

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested Chondron, a treatment made from a patient's own cartilage cells, for knee cartilage defects caused by osteoarthritis or injury. Ten participants received the cells during arthroscopic surgery. The study measured pain and knee function over 96 weeks to see if the treatment is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Chondron (autologous cultured chondrocytes)
What this could lead to
If successful, this could provide a way to repair knee cartilage and reduce pain in people with cartilage defects.
What could go wrong
This is a very small, completed post-marketing study with only 10 participants. Results may not apply to everyone, and long-term benefits or risks are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Yonsei University Severance Hospital

    Seoul, Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.